CCR1 blockade reduces interstitial inflammation and fibrosis in mice with glomerulosclerosis and nephrotic syndrome. - Wikidata - wikimedia - TriplyDB

CCR1 blockade reduces interstitial inflammation and fibrosis in mice with glomerulosclerosis and nephrotic syndrome.

CCR1 blockade reduces interstitial inflammation and fibrosis in mice with glomerulosclerosis and nephrotic syndrome.

http://www.wikidata.org/entity/Q45166206

about

The chemokine receptor CCR1 is constitutively active, which leads to G protein-independent, β-arrestin-mediated internalization Cytokine and Chemokine Expression in Kidneys during Chronic Leptospirosis in Reservoir and Susceptible Animal Models Pathogenic and protective role of macrophages in kidney disease Mefunidone attenuates tubulointerstitial fibrosis in a rat model of unilateral ureteral obstruction Over-expression of adenosine deaminase in mouse podocytes does not reverse puromycin aminonucleoside resistance.CDK inhibitor p21 is prosurvival in adriamycin-induced podocyte injury, in vitro and in vivo.Hepatocyte growth factor preferentially activates the anti-inflammatory arm of NF-κB signaling to induce A20 and protect renal proximal tubular epithelial cells from inflammation.Chemokine receptor Ccr1 drives neutrophil-mediated kidney immunopathology and mortality in invasive candidiasis Tubulointerstitial macrophage accumulation is regulated by sequentially expressed osteopontin and macrophage colony-stimulating factor: implication for the role of atorvastatin.Therapeutic targets for treating fibrotic kidney diseases Macrophage polarization in kidney diseases.Valproic acid attenuates proteinuria and kidney injury.The Interaction of Heparin Tetrasaccharides with Chemokine CCL5 Is Modulated by Sulfation Pattern and pH Ashwagandha attenuates TNF-α- and LPS-induced NF-κB activation and CCL2 and CCL5 gene expression in NRK-52E cells.Leukocytes induce epithelial to mesenchymal transition after unilateral ureteral obstruction in neonatal mice Liraglutide Reduces Both Atherosclerosis and Kidney Inflammation in Moderately Uremic LDLr-/- Mice CCR1/CCL5 (RANTES) receptor-ligand interactions modulate allogeneic T-cell responses and graft-versus-host disease following stem-cell transplantation.Association of urinary inflammatory markers and renal decline in microalbuminuric type 1 diabetics Hepatocyte growth factor exerts its anti-inflammatory action by disrupting nuclear factor-kappaB signaling Adriamycin alters glomerular endothelium to induce proteinuria Chemokine receptor CCR1 regulates inflammatory cell infiltration after renal ischemia-reperfusion injury.Efficient renal recruitment of macrophages and T cells in mice lacking the duffy antigen/receptor for chemokines.Inducible rodent models of acquired podocyte diseases.Chemokine profile in the sera and urine of patients with schistosomal glomerulopathy.Fibrogenesis in kidney transplantation: potential targets for prevention and therapy.New roles for innate immune response in acute and chronic kidney injuries.Immunotherapy for acute kidney injury.Tissue microenvironments define and get reinforced by macrophage phenotypes in homeostasis or during inflammation, repair and fibrosis.Targeting chemokines in proteinuria-induced renal disease.Tissues use resident dendritic cells and macrophages to maintain homeostasis and to regain homeostasis upon tissue injury: the immunoregulatory role of changing tissue environments.Danger control programs cause tissue injury and remodeling.The role of the immune system in idiopathic nephrotic syndrome: a review of clinical and experimental studies.Role of chemokines in proteinuric kidney disorders.The experimental model of nephrotic syndrome induced by Doxorubicin in rodents: an update.Macrophages in kidney injury, inflammation, and fibrosis.Links between coagulation, inflammation, regeneration, and fibrosis in kidney pathology.Available and incoming therapies for idiopathic focal and segmental glomerulosclerosis in adults.The chemokines CCR1 and CCRL2 have a role in colorectal cancer liver metastasis.Recoverability of renal functions after relief of partial ureteric obstruction of solitary kidney: impact of ferulic acid.Four danger response programs determine glomerular and tubulointerstitial kidney pathology: clotting, inflammation, epithelial and mesenchymal healing.

P2860

Q24337078-382EA1BA-8B2B-4AA4-85B7-70B26165E821 Q27345083-E8C7D01A-C497-4AC4-B5FC-E060E0C70994 Q27690812-CF15E517-8BF1-4FEA-807C-5EDF0ED5CF6B Q28547858-B48D22BE-EB94-4CDB-B38B-AD8D3F75F227 Q30986170-170911C4-B39A-4D91-A449-B9EE2E80AFAB Q33529367-E41C79BE-0004-4A5B-ACA6-8631B946DC6F Q33913784-BBBC4324-7D85-4B52-95F6-D650C86883F2 Q34390535-62C2FEFB-FCD2-4D1B-BF7D-A20CB87C4A8C Q35070511-92BEF5FD-4A27-43F0-8BF7-19ED4CD3D9DA Q35079607-3509CA3C-9EB9-44D3-A96C-F8C0EFE87CBA Q35737886-B75F7F1D-5597-45FD-99F7-B76278903E18 Q35758297-53EDAD19-1565-4183-A05D-60DF9111A966 Q35860612-530D2858-222A-431B-8ECE-B7CDC0272957 Q35868706-9FB8E1C6-FB63-45C1-BCF1-6ECBDE4470A7 Q35963225-194BDA5F-60F8-4E2E-AE5D-F651E764063F Q36228307-EE16533D-6043-43E4-BD9F-C3962DBF0BB0 Q36384883-C3D2A7AD-18C1-4338-8C29-E3970A0F3B66 Q36666878-BDFE4D86-E98C-4859-8660-E8AFFBF282AA Q36734848-94C69C24-8EA8-4EB0-BA8E-3C8B091A93FC Q37042146-95AEE14B-E3B7-46E3-8E10-E1DD2843403C Q37079501-602759A6-FF62-4508-948B-04C5F37CAEE9 Q37257139-2503BC18-CC9D-4DF6-922D-77612BF6EB8C Q37265903-496040AB-CC11-423C-B56E-AA3DA0C79AE4 Q37456159-9AEB789A-04B7-481B-B047-B9923CC6A6D5 Q37638064-6B5FB6CF-61BD-4D4D-8DD7-F92B5AA30A44 Q37832753-6003D5B0-F0D5-49C7-A3BA-BF4BE9E5B423 Q37991781-EADA7DC7-1A12-4309-BC29-077289AAE3EA Q38003021-08369D23-552A-4436-8E91-01BE1BB2D4B8 Q38026076-9BDB5BCE-196A-4400-BE9A-B0751A832070 Q38068399-E261CA8E-FC20-4D3C-A7B3-F299E18C5856 Q38113929-7823B93C-F928-4F1A-B1B7-EE85F537590E Q38152259-413E5187-0D95-413E-A78B-D9DC6C5D8ED8 Q38188747-CA41EBB3-E9C6-4B4E-B0AC-4B41DA5FCF04 Q38383524-421E6F90-E91E-47DF-B4C5-B51CAFAF8B1B Q38453872-1681E05C-28C4-4361-BF18-859E6258A37E Q38692356-FC143311-8B0C-4B8A-8754-B9DBEEC0E543 Q38805701-D6AE2A8C-44E7-4970-ADF8-4E06ABA3CE5C Q38834435-B80028A8-DC32-4135-9485-866F71E7E59E Q39251124-5926AC16-2FBC-4C30-8276-AFA2D4DFD620 Q39603954-08081E15-5216-456B-9EA2-C5D56E6F7BFC

P2860

CCR1 blockade reduces interstitial inflammation and fibrosis in mice with glomerulosclerosis and nephrotic syndrome.

http://www.wikidata.org/entity/Q45166206

description

2004 nî lūn-bûn

@nan

2004年の論文

@ja

2004年学术文章

@wuu

2004年学术文章

@zh

2004年学术文章

@zh-cn

2004年学术文章

@zh-hans

2004年学术文章

@zh-my

2004年学术文章

@zh-sg

2004年學術文章

@yue

2004年學術文章

@zh-hant

name

CCR1 blockade reduces intersti ...... erosis and nephrotic syndrome.

@en

CCR1 blockade reduces intersti ...... erosis and nephrotic syndrome.

@nl

type

label

CCR1 blockade reduces intersti ...... erosis and nephrotic syndrome.

@en

CCR1 blockade reduces intersti ...... erosis and nephrotic syndrome.

@nl

prefLabel

CCR1 blockade reduces intersti ...... erosis and nephrotic syndrome.

@en

CCR1 blockade reduces intersti ...... erosis and nephrotic syndrome.

@nl

P1433

Q45166206-46289A1A-0B1C-4AF0-8135-F59977742A07

P1476

Q45166206-1F9FF566-8C4D-43AE-8676-1AA93A9C3DC7

P2093

Q45166206-40E4AF97-6ACB-4342-9CF5-A32720FF88AA

Q45166206-410E6EE7-2FFA-4868-A87A-8BA151504507

Q45166206-52BF3CC9-8FC0-4D86-8C81-252C11B9D359

Q45166206-6CE5D043-D870-45A7-ABF8-6D79907CEECE

Q45166206-6DB56745-24D7-474E-80FD-84ED77D92B14

Q45166206-BC013E0B-A20E-4A33-B721-DBE106E45B56

Q45166206-CB5BF9FE-50A8-46A3-ABC7-0CCAC54C0564

Q45166206-CE9E334F-86C8-49F6-B2E7-8572F2830AA1

Q45166206-D864644B-0104-4627-A3BA-2C142666EE92

Q45166206-E5EEBBF5-B49D-4111-BDB6-10A2FDC76170

P2888

Q45166206-54C2B3C7-FCCB-46BA-A0BA-CFFE7E0DF655

P304

Q45166206-D8E58670-48E8-4BA6-9169-066BC01C4066

P31

Q45166206-12B80A3B-BFDF-4667-BAB4-3395A1DDBC60

P356

Q45166206-A2A4D127-763E-4A91-8E25-14DD472D61DB

P407

Q45166206-7D7E85DF-E8EC-45FF-95CF-849DEAE123AE

P433

Q45166206-1AF926C0-F220-48A4-ABF8-CF6995903800

P478

Q45166206-05F0E13B-AE17-4C5F-AB73-0A6B2F586092

P577

Q45166206-2576611D-A3A0-4DAE-AFE5-96086B8C479A

P5875

Q45166206-C3904B8C-DF9B-4E46-9544-5216D4A99998

P6179

Q45166206-DCCC422F-D95E-4168-BBF0-99CF6BB8B383

P698

Q45166206-6018B8AA-ED9D-409A-AB1E-B5FF1AA1B1F5

P356

J.1523-1755.2004.66038.X

P1433

Kidney International

P1476

CCR1 blockade reduces intersti ...... erosis and nephrotic syndrome.

@en

P2093

Detlef Schlöndorff

http://www.w3.org/2001/XMLSchema#string

Elias Berning

http://www.w3.org/2001/XMLSchema#string

Frank Strutz

http://www.w3.org/2001/XMLSchema#string

Hans-Joachim Anders

http://www.w3.org/2001/XMLSchema#string

Hermann-Josef Gröne

http://www.w3.org/2001/XMLSchema#string

Matthias Kretzler

http://www.w3.org/2001/XMLSchema#string

Richard Horuk

http://www.w3.org/2001/XMLSchema#string

Stephan Segerer

http://www.w3.org/2001/XMLSchema#string

Vaclav Eis

http://www.w3.org/2001/XMLSchema#string

Volker Vielhauer

http://www.w3.org/2001/XMLSchema#string

P2888

j.1523-1755.2004.66038.x

P304

2264-2278

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1523-1755.2004.66038.X

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

66

http://www.w3.org/2001/XMLSchema#string

P577

2004-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

8158825

http://www.w3.org/2001/XMLSchema#string

P6179

1037981443

http://www.w3.org/2001/XMLSchema#string

P698

15569315

http://www.w3.org/2001/XMLSchema#string